Literature DB >> 1688968

Differences in the central hypotensive actions of alpha-methyldopa and clonidine in the spontaneously hypertensive rat: contribution of neurons arising from the B3 and the C1 areas of the rostral ventrolateral medulla.

G Drolet1, V Aslanian, J Minson, M Morris, J Chalmers.   

Abstract

The rostral ventrolateral medulla (RVLM) is the proposed site of origin of bulbospinal excitatory vasomotor neurons, and this brainstem area gives rise to chemically distinct populations of neurons, including serotonin-containing neurons of the B3 group and epinephrine-containing neurons of the C1 group, which independently serve sympathoexcitatory functions. In the present study, we sought to establish (a) whether distinct and chemically specific pathways originating in the C1 or B3 regions are involved in the antihypertensive effects of alpha-methyldopa (methyldopa) and clonidine and (b) if so, whether these effects are related to an activation of alpha-adrenoceptors in these areas. Microinjections of methyldopa (6 nmol) or clonidine (5 nmol) were made in the C1 or B3 area in intact spontaneously hypertensive rats (SHR), pretreated with 5,7-dihydroxytryptamine (5,7-DHT) or with phentolamine. The microinjection of clonidine into both the B3 and the C1 area caused a rapid decrease in arterial pressure, whereas microinjection of methyldopa lowered the arterial pressure only after injection into the B3 area. Pretreatment with intracerebroventricular (i.c.v.) 5,7-DHT attenuated the hypotension produced by microinjection of clonidine into the B3 area, suggesting that this effect is mediated by serotonin-containing neurons. Central pretreatment with phentolamine reduced the hypotensive effects produced by injection of clonidine into either area and of methyldopa into the B3 region, consistent with previous suggestions that these central effects are mediated through alpha-adrenoceptors. These results suggest that both serotonin-containing and epinephrine-containing neurons contribute to the central action of clonidine, whereas the effects of methyldopa injection in RVLM appear to be mediated by serotonin-containing but not by epinephrine-containing neurons.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1688968     DOI: 10.1097/00005344-199001000-00019

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

1.  Interaction between clonidine and N-methyl-D-aspartate receptors in the caudal ventrolateral medulla of rats.

Authors:  Wei-Zhong Wang; Wen-Jun Yuan; Yan-Xia Pan; Chao-Shu Tang; Ding-Feng Su
Journal:  Exp Brain Res       Date:  2004-05-04       Impact factor: 1.972

Review 2.  Central serotonergic mechanisms in cardiovascular regulation.

Authors:  J Minson; J Chalmers; G Drolet; V Kapoor; I Llewellyn-Smith; E Mills; M Morris; P Pilowsky
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

3.  Cardiovascular effects of agmatine within the rostral ventrolateral medulla are similar to those of clonidine in anesthetized rats.

Authors:  Jun Yang; Wei-Zhong Wang; Fu-Ming Shen; Ding-Feng Su
Journal:  Exp Brain Res       Date:  2004-10-05       Impact factor: 1.972

4.  A novel mechanism of action for hypertension control: moxonidine as a selective I1-imidazoline agonist.

Authors:  P Ernsberger; M A Haxhiu; L M Graff; L A Collins; I Dreshaj; D L Grove; M E Graves; S G Schäfer; M O Christen
Journal:  Cardiovasc Drugs Ther       Date:  1994-03       Impact factor: 3.727

Review 5.  Different types of centrally acting antihypertensives and their targets in the central nervous system.

Authors:  P A van Zwieten; J P Chalmers
Journal:  Cardiovasc Drugs Ther       Date:  1994-12       Impact factor: 3.727

6.  Angiotensin-Converting Enzyme 2 in the Rostral Ventrolateral Medulla Regulates Cholinergic Signaling and Cardiovascular and Sympathetic Responses in Hypertensive Rats.

Authors:  Yu Deng; Xing Tan; Miao-Ling Li; Wei-Zhong Wang; Yang-Kai Wang
Journal:  Neurosci Bull       Date:  2018-10-15       Impact factor: 5.203

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.